Can we wean patients with inflammatory arthritis from biological therapies?

Publication date: Available online 19 October 2019Source: Autoimmunity ReviewsAuthor(s): Christopher J. Edwards, Galeazzi Mauro Galeazzi, Salvatore Bellinvia, Ariana Ringer, Theodoros Dimitroulas, George D. KitasAbstractBiological therapies have represented a cornerstone in the treatment of immune-mediated inflammatory diseases. Their advent combined with implementation of a treat-to-target approach has meant that remission or low disease activity are now realistic targets for treatment achieved by a significant number of patients. However, biologicals are not risk free and their elevated costs continue to present an important economic burden to national healthcare services.“Can we wean patients with inflammatory arthritis from biological therapies?”Over the last decade this question has become increasingly important as to define the best management strategies in terms of efficacy, safety and economic outcomes. Not surprisingly this has generated an interesting debate as to whether reasons to taper biologics outweigh reasons not to taper and evidence in support of either of these schools of thought is persistently growing.AimIn this article we reviewed the contents of the relevant session from the 2019 Controversies in Rheumatology and Autoimmunity meeting in Florence.
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research

Related Links:

A 56-year-old automobile mechanic was referred to our rheumatology service by his orthopedist to evaluate left posterior knee pain and swelling that had been present for three months. The patient had undergone bilateral total knee arthroplasties (TKAs) for sports-related osteo­arthritis three years before. In addition to the knee pain, the patient described several years of... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Home Slider Rheumatoid Arthritis knee arthroplasty knee swelling popliteal cyst synovitis Source Type: research
In this report, we present the case of... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Rheumatoid Arthritis anti-CD20 therapy Pericarditis rituximab Source Type: research
(Natural News) Lyme disease and rheumatoid arthritis are two different diseases that share many symptoms. A patient will benefit from knowing how to tell them apart. The diseases have different origins. Lyme disease is a bacterial disease caused by the bacteria Borrelia burgdorferi, which infect humans via tick bites. Meanwhile, rheumatoid arthritis stems from a mixture of...
Source: - Category: Consumer Health News Source Type: news
CONCLUSION: Taken together, the results of this investigation revealed the part of molecular and immunological mechanisms of drug Mannuronic acid (M2000) in treatment of RA, based on chemokine ligands and receptors mediated processes. PMID: 31729947 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
AbstractObjectivesThe effect of age on the Health Assessment Questionnaire Disability Index (HAQ-DI) scores of rheumatoid arthritis (RA) patients and the validity of adopting HAQ-DI  3-year treatment under T2T were evaluated. The relationships between the HAQ-DI score at follow-up (HAQ) and 28-joint Disease Activity Score with C-reactive protein, Sharp/van der Heijde Score, age at follow-up, and HAQ-DI at baseline were statistically evaluated with best subset regression analy sis in groups separated according to age and the EULAR response. CDC status was evaluated with a chi-square test.ResultsThe HAQ score signific...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
ConclusionOur study indicates RA-ILD among Blacks is predominantly a disease of elderly females with higher rates of GERD and CVD risk factors. Further studies are needed to identify the pathogenetic differences accounting for the gender distribution of RA-ILD among Black and White populations.Key Points•First study to assess ILD among predominantly Black RA patients.•The prevalence of RA-associated ILD was 6.36%, affecting mostly women in their sixth decade with seropositive disease.•COPD was the most common airway disease among non-RA-ILD Black population.•GERD was found in approximately one-third of ...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
This article describes the relevant anatomy, biomechanics, and classification system, and provides an up-to-date literature-based review of treatment options, including acute repair and various reconstruction techniques. It also helps guide surgeons in making decisions regarding a systematic treatment algorithm for these injuries.
Source: Orthopedic Clinics of North America - Category: Orthopaedics Authors: Source Type: research
AbstractMacrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis, is a frequently fatal complication of a variety of pediatric inflammatory disorders. MAS has been most commonly associated with systemic juvenile idiopathic arthritis (sJIA), as approximately 10% of children with sJIA develop fulminant MAS, with another 30 –40% exhibiting a more subclinical form of the disease. Children with other rheumatologic conditions such as systemic lupus erythematosus and Kawasaki disease are also at risk for MAS. Moreover, MAS also complicates various genetic autoinflammatory disorders such a...
Source: Pediatric Drugs - Category: Pediatrics Source Type: research
In this study, novel water-soluble carbon dots (CDs) with anti-gout effect, named Puerariae lobatae Radix CDs (PLR-CDs), are reported. PLR-CDs were synthesized with an improved pyrolysis method at 300 °C, and their characterization was performed with multifaceted approaches, such as transmission electron microscopy (TEM) and ultraviolet–visible (UV–vis) and Fourier-transform infrared (FTIR) spectroscopy. In addition, the biocompatibility of PLR-CDs was studied using the cell counting kit (CCK)-8 in LO2 cells and RAW264.7 cells, and the anti-gout activity of PLR-CDs was examined on animal models ...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
ConclusionLong-term data from patients with RA treated in routine clinical practice in Korea showed that CT-P13 had a comparable drug retention rate to reference infliximab, with similar efficacy and an acceptable safety identifierNCT01965132.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Allergy & Immunology | Arthritis | Rheumatology | Schools